An association between BPDE-like DNA adduct levels and P53 gene mutation in pterygium

Molecular Vision

Volumn 12, Issue , 2006, Pages 1687-1691

  Lai, Te Jen ^a   Tsai, Yi Yu ^b   Cheng, Ya Wen ^a   Chiang, Chun Chi ^b   Lee, Huei ^a   Chou, Ming Chih ^a   Chang, Julia Hueimei ^a,c  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPOXIDE; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DNA ADDUCT; DNA EXTRACTION; DNA SEQUENCE; EPITHELIUM CELL; EXON; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PTERYGIUM;

7,8-DIHYDRO-7,8-DIHYDROXYBENZO(A)PYRENE 9,10-OXIDE; AGED; AGED, 80 AND OVER; DEOXYGUANOSINE; DNA ADDUCTS; FEMALE; GENES, P53; GUANINE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PTERYGIUM; STAINING AND LABELING; THYMINE; TISSUE DISTRIBUTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33846159826     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Tan DT, Lim AS, Goh HS, Smith DR. Abnormal expression of the p53 tumor suppressor gene in the conjunctiva of patients with pterygium. Am J Ophthalmol 1997; 123:404-5.
2. Dushku N, Reid TW. P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. Curr Eye Res 1997; 16:1179-92.
3. Onur C, Orhan D, Orhan M, Dizbay Sak S, Tulunay O, Irkec M. Expression of p53 protein in pterygium. Eur J Ophthalmol 1998; 8:157-61.
4. Chowers I, Pe'er J, Zamir E, Livni N, Ilsar M, Frucht-Pery J. Proliferative activity and p53 expression in primary and recurrent pterygia. Ophthalmology 2001; 108:985-8.
5. Weinstein O, Rosenthal G, Zirkin H, Monos T, Lifshitz T, Argov S. Overexpression of p53 tumor suppressor gene in pterygia. Eye 2002; 16:619-21.
6. Tan DT, Tang WY, Liu YP, Goh HS, Smith DR. Apoptosis and apoptosis related gene expression in normal conjunctiva and pterygium. Br J Ophthalmol 2000; 84:212-6.
7. Dushku N, Hatcher SL, Albert DM, Reid TW. p53 expression and relation to human papillomavirus infection in pingueculae, pterygia, and limbal tumors. Arch Ophthalmol 1999; 117:1593-9.
8. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53.
9. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994; 54:4855-78.
10. Hussain SP, Harris CC. Molecular epidemiology of human cancer: contribution of mutation spectra studies of tumor suppressor genes. Cancer Res 1998; 58:4023-37.
11. Tsai YY, Cheng YW, Lee H, Tsai FJ, Tseng SH, Chang KC. P53 gene mutation spectrum and the relationship between gene mutation and protein levels in pterygium. Mol Vis 2005; 11:50-5.
12. Lee H, Su SY, Liu KS, Chou MC. Correlation between meteorological conditions and mutagenicity of airborne particulate samples in a tropical monsoon climate area from Kaohsiung City, Taiwan. Environ Mol Mutagen 1994; 23:200-7.
13. Kuo CY, Cheng YW, Chen CY, Lee H. Correlation between the amounts of polycyclic aromatic hydrocarbons and mutagenicity of airborne particulate samples from Taichung City, Taiwan. Environ Res 1998; 78:43-9.
14. Hussain SP, Amstad P, Raja K, Sawyer M, Hofseth L, Shields PG, Hewer A, Phillips DH, Ryberg D, Haugen A, Harris CC. Mutability of p53 hotspot codons to benzo(a)pyrene diol epoxide (BPDE) and the frequency of p53 mutations in nontumorous human lung. Cancer Res 2001; 61:6350-5.
15. Cheng YW, Hsieh LL, Lin PP, Chen CP, Chen CY, Lin TS, Su JM, Lee H. Gender difference in DNA adduct levels among nonsmoking lung cancer patients. Environ Mol Mutagen 2001; 37:304-10.
16. Schneider BG, John-Aryankalayil M, Rowsey JJ, Dushku N, Reid TW. Accumulation of p53 protein in pterygia is not accompanied by TP53 gene mutation. Exp Eye Res 2006; 82:91-8.
17. Saw SM, Banerjee K, Tan D. Risk factors for the development of pterygium in Singapore: a hospital-based case-control study. Acta Ophthalmol Scand 2000; 78:216-20.
18. Saw SM, Tan D. Pterygium: prevalence, demography and risk factors. Ophthalmic Epidemiol 1999; 6:219-28.
19. McCarty CA, Fu CL, Taylor HR. Epidemiology of pterygium in Victoria, Australia. Br J Ophthalmol 2000; 84:289-92.
20. Hill JC, Maske R. Pathogenesis of pterygium. Eye 1989; 3:218-26.
21. Moran DJ, Hollows FC. Pterygium and ultraviolet radiation: a positive correlation. Br J Ophthalmol 1984; 68:343-6.
22. Coroneo MT. Pterygium as an early indicator of ultraviolet insolation: a hypothesis. Br J Ophthalmol 1993; 77:734-9.
23. Spierer A, Rosner M, Belkin M. Pterygium, solar ultraviolet radiation and myopia. Metab Pediatr Syst Ophthalmol 1985; 8:47-8.
24. Gazzard G, Saw SM, Farook M, Koh D, Widjaja D, Chia SE, Hong CY, Tan DT. Pterygium in Indonesia: prevalence, severity and risk factors. Br J Ophthalmol 2002; 86:1341-6.
25. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci U S A 1991; 88:10124-8.
26. Dumaz N, Stary A, Soussi T, Daya-Grosjean L, Sarasin A. Can we predict solar ultraviolet radiation as the causal event in human tumours by analysing the mutation spectra of the p53 gene? Mutat Res 1994; 307:375-86.
27. Hainaut P, Vahakangas K. p53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol Biol (Paris) 1997; 45:833-44.
28. Wei M, Wanibuchi H, Morimura K, Iwai S, Yoshida K, Endo G, Nakae D, Fukushima S. Carcinogenicity of dimethylarsinic acid in male F344 rats and genetic alterations in induced urinary bladder tumors. Carcinogenesis 2002; 23:1387-97.
29. International Agency for Research on Cancer, Polynuclear aromatic compounds, Part 1. Chemical, environmental, and experimental data, in: IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans, vol 32. World Health Organization, International Agency for Research on Cancer, Lyon, France; 1983.
30. International Agency for Research on Cancer, Tobacco smoking, IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans vol 38, IARC, Lyon, France; 1986.
31. Hainaut P, Pfeifer GP. Patterns of p53 G - >T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001; 22:367-74.
32. Denissenko MF, Pao A, Tang M, Pfeifer GP. Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53. Science 1996; 274:430-2.
33. Pfeifer GP, Denissenko MF. Formation and repair of DNA lesions in the p53 gene: relation to cancer mutations? Environ Mol Mutagen 1998; 31:197-205.
34. Smith LE, Denissenko MF, Bennett WP, Li H, Amin S, Tang M, Pfeifer GP. Targeting of lung cancer mutational hotspots by polycyclic aromatic hydrocarbons. J Natl Cancer Inst 2000; 92:803-11.
35. Reisman D, McFadden JW, Lu G. Loss of heterozygosity and p53 expression in Pterygium. Cancer Lett 2004; 206:77-83.
36. Shimmura S, Ishioka M, Hanada K, Shimazaki J, Tsubota K. Telomerase activity and p53 expression in pterygia. Invest Ophthalmol Vis Sci 2000; 41:1364-9.